Heron Therapeutics (NASDAQ:HRTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Heron Therapeutics (NASDAQ:HRTX) to a sell rating in a report released on Saturday morning.

HRTX has been the subject of several other reports. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Needham & Company LLC cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright cut their price objective on shares of Heron Therapeutics to $2.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $0.34 on Friday. Heron Therapeutics has a 12-month low of $0.32 and a 12-month high of $1.57. The company’s 50 day moving average price is $0.44 and its two-hundred day moving average price is $0.83. The firm has a market cap of $63.41 million, a PE ratio of -1.86 and a beta of 1.65. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter. The business had revenue of $37.67 million during the quarter, compared to analyst estimates of $42.19 million. Heron Therapeutics had a negative net margin of 20.53% and a negative return on equity of 7,747.30%. Equities research analysts predict that Heron Therapeutics will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of Heron Therapeutics by 39.1% during the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after buying an additional 6,858 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Heron Therapeutics by 5.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after acquiring an additional 11,716 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Heron Therapeutics during the 2nd quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Heron Therapeutics by 19.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 13,544 shares in the last quarter. Finally, Advisory Services Network LLC grew its position in Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 18,114 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.